Patients who received daily humidification of the mouth and throat region starting at day one of radiation therapy treatment spent nearly 50% fewer days in the hospital to manage their side effects, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium being held at the JW Marriott Camelback Inn Resort & Spa in Scottsdale, Arizona, February 20 – 22, 2014.[1]
The study was conducted by the Trans Tasman Radiation Oncology Group (TROG) and evaluated 210 head and neck cancer patients in New Zealand and Australia from June 2007 through June 2011. The patients participating in this Phase III trial were randomized to institutional standard of care (control arm) or humidification (HUM) using the Fisher & Paykel Healthcare MR880 humidifier.* The humidified air is delivered through the nose via a plastic interface (mask-type apparatus) that can be worn by patients while sleeping or while sitting during the day.
…these results are encouraging, particularly given the signals favoring humidification were seen across clinician-reported outcomes, patient-reported outcomes and independent data such as hospitalizations…
Managing side effects
Patients began HUM on day one of radiation therapy and continued until the ulceration their mouth and throat had resolved. On average, HUM patients spent 57% as many days in the hospital to manage side effects (control = 4.1 days vs. HUM = 2.3 days). The return of eating patterns to close to normal was also significantly higher at three months after radiotherapy in the group using humidifiers. (Nutritional Mode score at 20 weeks, a clinician-reported assessment of nutritional status, control = 4.8 vs. HUM = 5.23.)
Reduction in symptom burden
Only 43 patients (42% of the patients in the HUM arm) met the defined benchmark of HUM compliance and were able to contribute to the per protocol (PP) analysis; the mean average use of humidification for these patients was 3.6 hours per day (range of use for all patients = 0-14 hours/day). In patients who met the HUM compliance benchmark, the area under the curve for CTCAE version 3.0 functional mucositis score (a clinician assessment of mucositis symptom burden for patients) was reduced (control = 8.63 vs. HUM PP = 6.74). The proportion of compliant HUM patients who never required a feeding tube was also increased (control = 0.73 vs. HUM PP = 0.85). There was also a trend for patients to report a reduction in symptom burden when using humidification but only in those patients compliant in using the humidifier.
Quality of Life
?Mucositis [or inflammation and ulceration of the mouth and throat, is a painful side effect of radiation therapy that] can negatively affect patients? quality of life. This study has provided efficacy signals consistent with a role for humidification in reducing symptom burden for patients during radiotherapy for head and neck cancer. Preventing or reducing hospitalizations may also mean it is cost effective. The rationale for using humidification is based on the fact that moisturizing wounds generally helps them heal faster,? noted Andrew Macann, MBcHB, FRANZCR, lead author of the study and a radiation oncologist at Auckland City Hospital in Auckland, New Zealand. ?These results are encouraging, particularly given the signals favoring humidification were seen across clinician-reported outcomes, patient-reported outcomes and independent data such as hospitalizations. Although patients in the study did not use the humidifiers as much as was hoped, we obtained feedback about why some patients did not like using the humidifier. Our next step is to work at increasing the proportion of patients who use the humidifier effectively.?
* This product is not currently available in the United States. For more information in other regions, click here.
For more information:
[1] Domiciliary Humidification Reduces Symptom Burden and Hospital Admissions Associated With Mucositis During Radiotherapy For Head And Neck Cancer: Trans Tasman Radiation Oncology Group (TROG) 07.03 RadioHUM Randomised Phase III Trial Results, was presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium by Andrew Macann, MBcHB, FRANZCR, lead author of the study and a radiation oncologist at Auckland City Hospital in Auckland, New Zealand.
Copyright ? 2014 InPress Media Group/Sunvalley Communication. All rights reserved. Republication or redistribution of InPress Media Group/Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent ofInPress Media Group/Sunvalley Communication. InPress Media Group/Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco’Zine and Oncozine are registered trademarks and trademarks of Sunvalley Communication around the world.
